Ligachem Biosciences expands ADC pipeline with new NovaRock antibody license

CAR-T Digest - August 2020

24 February 2026: Ligachem Biosciences expands ADC pipeline with new NovaRock antibody license

LigaChem Biosciences announced that it has signed a new technology licensing agreement with U.S.-based NovaRock Biotherapeutics to in-license an antibody targeting a novel anticancer marker for the development of an antibody-drug conjugate candidate
This agreement is separate from the two antibody licensing deals signed between the companies in June 2025, further strengthening their ongoing collaboration and expanding LigaChem’s ADC portfolio
Under the terms of the deal, LigaChem has secured exclusive global rights to develop and commercialize an ADC based on the newly licensed antibody, although financial details and specific target information were not disclosed
The antibody is directed against a new marker expressed in solid tumors with high unmet medical need, and LigaChem plans to leverage its proprietary ConjuALL ADC platform to generate next-generation ADC candidates from this asset
Aligned with its “VISION 2030” strategy to advance three to five new ADC candidates annually into clinical development, LigaChem continues to expand its pipeline through domestic and international partnerships, positioning ADC innovation as a central pillar of its long-term growth